Loading...
•
Dec 31, 2020
Vir Q4 2020 Earnings Report
Vir closed 2020 delivering strong progress across its entire development pipeline and reported financial results.
Key Takeaways
Vir Biotechnology reported fourth-quarter revenue of $1.7 million, primarily due to the timing of research activities under the HIV and TB grants with the Bill & Melinda Gates Foundation. The company's net loss for the quarter was $105.6 million, or $0.83 per share. As of December 31, 2020, the company had approximately $736.9 million in cash, cash equivalents and investments.
Expanded GSK collaboration to include research and development of new therapies for influenza and other respiratory viruses.
Initiated ACTIV-3 Phase 3 trial evaluating VIR-7831 for the treatment of hospitalized adults with COVID-19.
Entered into a clinical collaboration with Gilead Sciences, Inc. to evaluate VIR-2218 in a Phase 2 combination therapy trial for chronic HBV.
Initiated a Phase 1 clinical trial of VIR-1111, an investigational HIV T cell vaccine.
Revenue by Segment
Forward Guidance
Vir Biotechnology anticipates a transformational year ahead with multiple promising candidates and pending data from Phase 3 studies. The company also expects to initiate additional trials and present clinical data in the coming quarters.
Positive Outlook
- Expected primary endpoint results from COMET-ICE in Q1 2021.
- Potential Emergency Use Authorization and Biologics License Application submission for VIR-7831.
- Initiation of AGILE trial to evaluate VIR-7832 in Q1 2021.
- Initial results for Eli Lilly’s Phase 2 BLAZE-4 trial expected in the first half of 2021.
- Initiation of COMET-TAIL and COMET-STAR trials in Q2 2021.
Challenges Ahead
- Unexpected safety or efficacy data observed during preclinical or clinical studies.
- Difficulties in collaborating with other companies or government agencies.
- Challenges in accessing manufacturing capacity.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...